首页> 外文OA文献 >PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

【2h】

PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

机译：帕尼单抗+ Folfox与西妥昔单抗+ Folfiri相比一线治疗PCN171成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vargas-Valencia J; Garcia Perlaza J;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): the CECOG/CORE1.2.001 trial [J] . I. Koza Sr., F. Wrba, D. Vrbanec, Memo - Magazine of European medical oncology . 2009,第3期

机译：一线接受FOLFOX6 +西妥昔单抗（FX + C）或FOLFIRI +西妥昔单抗（FF + C）治疗的转移性结直肠癌（mCRC）患者（pts）的KRAS状态与临床结局的相关性：CECOG / CORE1.2.001试验
2. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro) [J] . Michl M., Stintzing S., Fischer von Weikersthal L., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第8期

机译：在接受一线FOLFIRI加西妥昔单抗或贝伐单抗治疗的KRAS外显子2野生型和扩展RAS野生型转移性结直肠癌患者中，CEA反应与肿瘤反应和生存相关（FIRE-3试验）（aEuro）
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Treatment patterns and cost-effectiveness of therapeutic sequences among advanced colorectal cancer patients. [D] . Parikh, Rohan C. 2015

机译：晚期大肠癌患者的治疗模式和治疗序列的成本效益。
6. Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin Fluorouracil and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer [O] . Liangliang Bai, Pengfei Zhang, Kexun Zhou, 2019

机译：一线西妥昔单抗联合白细胞素氟尿嘧啶和奥沙利铂（FOLFOX-4）与FOLFOX-4在RAS野生型转移性结直肠癌患者中的成本效果分析
7. PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) + BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT)) [O] . Torrecillas L, Vargas J 2008

机译：PCN33基于伊立替康（FOLFIRI）+贝伐单抗或西妥昔单抗的转移性大肠癌（MCRC）一线治疗的经济评估，由KRAS基因（野生型（WT）或突变型（MT））调整

PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

著录项

引文网络

相似文献

相关主题

期刊订阅